Cigna’s Evernorth Health Services segment reported 12% year-over-year revenue growth in fiscal Q4 2025, reaching $38.2 billion. This performance was fueled by a 9% increase in care solutions revenue and a 15% rise in specialty pharmacy services, reflecting strong adoption of integrated benefit models by large self-funded employers. Evernorth now represents 45% of consolidated revenues, up from 42% a year earlier, underscoring its expanding contribution to Cigna’s top-line and overall profitability.

During 2025, Cigna processed 1.35 billion pharmacy scripts, up 8% year-over-year, and opened three new specialty pharmacy fulfillment centers in Phoenix, Atlanta and Nashville. The insurer signed network agreements with two major hospital systems, adding 250 new pharmacy access points. Management projects that continued investment in home delivery and clinical support programs will drive low-double-digit growth in pharmacy revenues through 2027.

Cigna’s current forward P/E ratio stands at 11.8x based on fiscal 2026 earnings estimates, compared with an industry average of 15.5x. Its price-to-book multiple of 1.6x is below the sector median of 2.2x. Analysts note that CI’s dividend yield of 1.4% and a 15% upside to consensus price targets suggest the stock remains undervalued, particularly given accelerating growth in high-margin care solutions.

In 2025, Cigna returned $4.2 billion to shareholders, including $2.5 billion in share repurchases (representing 3.2% of shares outstanding) and $1.7 billion in dividends. The board authorized a $5 billion buyback program in November 2025 and raised the quarterly dividend by 8% to $1.25 per share. Management reaffirmed its capital allocation framework targeting a 13%–15% return on invested capital and at least 30% of adjusted earnings returned to investors annually.